Press Releases

Offers new treatment option for genotype 1 HCV patients in Japan who are interferon-ineligible/intolerant, or did not previously respond to treatment Japanese HCV patients in urgent need of care now have opportunity for cure, including older patients and those...

genOway guarantees freedom to operate (FTO) and offers important gains in conditional knockout development time for industry scientists Lyon, France, July 2, 2014 - genOway (Alternext-NYSE Euronext: ALGEN; ISIN: FR0004053510), the biotechnology company dedicated to the development of genetically modified...

Cancer immunotherapy research departments need to break their obsession with the latest flavour of the month - checkpoint inhibitors - and concentrate more on combining checkpoint inhibitors with APC activators, thinks Dr. Frederic Triebel, the founder of the French...

Proveblue(R) is the methylthioninium chloride or Methylene Blue active substance patented by Provepharm, compliant with current European Pharmacopeia standards Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie (DFKC),...

Ozenoxacin, a novel bactericidal non-fluorinated quinolone that successfully completed a first phase III clinical trial in adult and paediatric patients with impetigo, is available from Ferrer for licensing and commercialisation Ferrer, a privately-held Spanish pharmaceutical company,...

There are 5 million persons suffering from asthma in Great Britain and despite medication, half a million of these persons have symptoms which limit their daily life. In some serious cases, the asthma develop may into a life-threatening condition....

The global market for Point of Care diagnostics is set to sharply increase by 2018 and Europe’s market is becoming increasingly competitive due to its low barriers of entry. Based on this information SMi is proud...